Richwood Investment Advisors LLC Has $573,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Richwood Investment Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,833 shares of the biopharmaceutical company’s stock after selling 380 shares during the quarter. Richwood Investment Advisors LLC’s holdings in Gilead Sciences were worth $573,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. grew its holdings in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 238 shares during the last quarter. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth approximately $29,000. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Financial Connections Group Inc. bought a new position in Gilead Sciences in the 2nd quarter worth approximately $34,000. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by insiders.

Gilead Sciences Stock Up 1.2 %

NASDAQ GILD traded up $1.03 during trading on Tuesday, hitting $86.08. The stock had a trading volume of 1,207,527 shares, compared to its average volume of 7,107,171. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The company’s 50-day moving average price is $80.07 and its two-hundred day moving average price is $72.42. The company has a market capitalization of $107.24 billion, a PE ratio of 236.25, a P/E/G ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.58%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Barclays lifted their target price on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Truist Financial lifted their price objective on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price objective on shares of Gilead Sciences in a report on Monday, September 16th. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Finally, BMO Capital Markets increased their price target on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Ten analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $84.83.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.